CMV-TCR-T Cells for CMV Infection After Allogenic HSCT

Exclusion Criteria

• •1. Patients with active aGVHD one day before TCR-T cell infusion.
• •2. Patients with severe kidney disease (Cr \> 3×normal value), liver damage (TBIL \>2.5×upper limit of normal value, ALT and AST \> 3×upper limit of normal value) or heart failure (NYHA heart function grade IV) one week before TCR-T cell infusion.
• •3. Anticipated to take immunosuppressive hormones on the day of TCR-T cell infusion.
• •4. Have other malignancies.
• •5. Have relapsed and uncontrolled hematologic malignancies.
• •6. Serologically positive for HIV-Ab or TAP-ab.
• •7. Pregnant or lactating women.
• •8. Anticipated to have other cell therapies in 4 week post TCR-T cell infusion.
• •9. Participated in any other clinical study of drugs and medical devices before 30 days of enrollment.
• •11\. Any condition that would, in the investigator's judgment, interfere with full participation in the study, including administration of study drug and attending required study visits; pose a significant risk to the subject; or interfere with interpretation of study data.
• •1. Positive for any of the following: HbsAg, HBeAg, HBV-DNA, HCV-Ab, HCV-RNA, HIV-Ab, TP-Ab, EBV-DNA or CMV-DNA;
• •2. Other uncontrolled infection;
• •3. Have taken immunosuppressive drugs 1 week before PBMC collection;
• •4. Any condition that would, in the investigator's judgment, make it unsuitable for the donors to be enrolled.